4.8 Article

Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma

期刊

ONCOGENE
卷 35, 期 16, 页码 2020-2030

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.267

关键词

-

资金

  1. Swiss National Science Fund [31003A-138460]
  2. Sciex [F-80016-02-01]
  3. Cancer League Canton Zurich
  4. Swiss National Science Foundation (SNF) [31003A_138460] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

Current treatment regimens for rhabdomyosarcoma (RMS), the most common pediatric soft tissue cancer, rely on conventional chemotherapy, and although they show clinical benefit, there is a significant risk of adverse side effects and secondary tumors later in life. Therefore, identifying and targeting sub-populations with higher tumorigenic potential and self-renewing capacity would offer improved patient management strategies. Hedgehog signaling has been linked to the development of embryonal RMS (ERMS) through mouse genetics and rare human syndromes. However, activating mutations in this pathway in sporadic RMS are rare and therefore the contribution of hedgehog signaling to oncogenesis remains unclear. Here, we show by genetic loss-and gain-of-function experiments and the use of clinically relevant small molecule modulators that hedgehog signaling is important for controlling self-renewal of a subpopulation of RMS cells in vitro and tumor initiation in vivo. In addition, hedgehog activity altered chemoresistance, motility and differentiation status. The core stem cell gene NANOG was determined to be important for ERMS self-renewal, possibly acting downstream of hedgehog signaling. Crucially, evaluating the presence of a subpopulation of tumor-propagating cells in patient biopsies identified by GLI1 and NANOG expression had prognostic significance. Hence, this work identifies novel functional aspects of hedgehog signaling in ERMS, redefines the rationale for its targeting as means to control ERMS self-renewal and underscores the importance of studying functional tumor heterogeneity in pediatric cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Obstetrics & Gynecology

Clinical and Histologic Evaluation of the Hysterotomy Site and Fetal Membranes after Open Fetal Surgery for Fetal Spina Bifida Repair

Nicole Ochsenbein-Kolble, Simone Brandt, Peter Bode, Franziska Krahenmann, Margaret Husler, Ueli Mohrlen, Luca Mazzone, Martin Meuli, Roland Zimmermann

FETAL DIAGNOSIS AND THERAPY (2019)

Article Microbiology

Francisella tularensis Periprosthetic Joint Infections Diagnosed with Growth in Cultures

Ales Chrdle, Tomas Trnka, David Musil, Sandro F. Fucentese, Peter Bode, Peter M. Keller, Yvonne Achermann

JOURNAL OF CLINICAL MICROBIOLOGY (2019)

Article Oncology

Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death

Johannes Ommer, Joanna L. Selfe, Marco Wachtel, Eleanor M. O'Brien, Dominik Laubscher, Michaela Roemmele, Stephanie Kasper, Olivier Delattre, Didier Surdez, Gemma Petts, Anna Kelsey, Janet Shipley, Beat W. Schafer

CANCER RESEARCH (2020)

Article Cardiac & Cardiovascular Systems

Right atrial pathology in arrhythmogenic right ventricular dysplasia

Guoliang Li, Guy H. Fontaine, Shuanliang Fan, Yang Yan, Peter K. Bode, Firat Duru, Robert Frank, Ardan M. Saguner

CARDIOLOGY JOURNAL (2019)

Article Biochemistry & Molecular Biology

Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma

Eva Brack, Marco Wachtel, Anja Wolf, Andres Kaech, Urs Ziegler, Beat W. Schafer

CELL DEATH AND DIFFERENTIATION (2020)

Correction Oncology

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (vol 32, pg 345, 2019)

H. Pfeifer, G. Cazzaniga, V. H. J. van der Velden, J. M. Cayuela, B. Schafer, O. Spinelli, S. Akiki, S. Avigad, I. Bendit, K. Borg, H. Cave, L. Elia, S. C. Reshmi, G. Gerrard, S. Hayette, M. Hermanson, A. Juh, T. Jurcek, M. C. Chillon, C. Homburg, G. Martinelli, V. Kairisto, T. Lange, T. Lion, M. C. Mueller, F. Pane, L. Rai, C. Damm-Welk, T. Sacha, S. Schnittger, T. Touloumenidou, H. Valerhaugen, P. Vandenberghe, J. Zuna, H. Serve, E. Herrmann, S. Markovic, J. J. M. van Dongen, O. G. Ottmann

LEUKEMIA (2020)

Article Immunology

Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies

Amandine Bovay, Sina Nassiri, Helene Maby-El Hajjami, Paula Marcos Mondejar, Rama S. Akondy, Rafi Ahmed, Benton Lawson, Daniel E. Speiser, Silvia A. Fuertes Marraco

VACCINE (2020)

Article Oncology

Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma

Guenther H. S. Richter, Tim Hensel, Oxana Schmidt, Vadim Saratov, Kristina von Heyking, Fiona Becker-Dettling, Carolin Prexler, Hsi-Yu Yen, Katja Steiger, Simone Fulda, Uta Dirksen, Wilko Weichert, Shudong Wang, Stefan Burdach, Beat W. Schaefer

CANCERS (2020)

Article Biology

NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

Joana G. Marques, Berkley E. Gryder, Blaz Pavlovic, Yeonjoo Chung, Quy A. Ngo, Fabian Frommelt, Matthias Gstaiger, Young Song, Katharina Benischke, Dominik Laubscher, Marco Wachtel, Javed Khan, Beat W. Schafer

Article Multidisciplinary Sciences

Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage

Berkley E. Gryder, Marco Wachtel, Kenneth Chang, Osama El Demerdash, Nicholas G. Aboreden, Wardah Mohammed, Winston Ewert, Silvia Pomella, Rossella Rota, Jun S. Wei, Young Song, Benjamin Z. Stanton, Beat Schafer, Christopher R. Vakoc, Javed Khan

ISCIENCE (2020)

Article Genetics & Heredity

High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma

Melanie Generali, Sampoorna Satheesha, Peter K. Bode, Debora Wanner, Beat W. Schaefer, Elisa A. Casanova

Summary: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and fusion-positive RMS (FPRMS) with PAX3/7-FOXO1 expression has a worse prognosis compared to fusion-negative RMS (FNRMS). This study found no stable cancer stem cell subpopulation in FPRMS, unlike FNRMS. The high frequency of tumor propagating stem-like cells in FPRMS may explain their higher propensity for metastasis and relapse.
Article Medicine, General & Internal

Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung Cancer

Jurgen Hetzel, Laetitia A. A. Mauti, Jonas Winkler, Sabine Cardoso Almeida, Philip Jermann, Miklos Pless, Lukas Bubendorf, Peter Karl Bode, Maik Haentschel

Summary: Personalized treatment of metastatic non-squamous NSCLC requires comprehensive molecular characterization of the tumor, including detection of driver mutations and PD-L1 expression. Different sampling techniques may be necessary to obtain sufficient tumor material. This case report highlights the importance of biopsy technique for precise tumor characterization. Only EBUS-TBLNC provided complete characterization, demonstrating PD-L1 expression without actionable genetic alterations.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma

Silvia Pomella, Sara G. Danielli, Rita Alaggio, Willemijn B. Breunis, Ebrahem Hamed, Joanna Selfe, Marco Wachtel, Zoe S. Walters, Beat W. Schaefer, Rossella Rota, Janet M. Shipley, Simone Hettmer

Summary: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and adolescents, characterized by aberrant muscle differentiation. Abnormalities in the regulatory transcription factors (MRFs) involved in skeletal muscle development contribute to tumorigenesis in RMS. Core regulatory circuitries (CRCs) and hierarchically organized subsets of cells play a role in maintaining the disease-driving fusion oncogene and promoting malignancy in RMS. Understanding the genetic and epigenetic framework of abnormal muscle differentiation in RMS provides insights into its mechanisms and potential therapeutic strategies.

CANCERS (2023)

Article Oncology

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

Nagjie Alijaj, Sandrine Moutel, Zelia L. Gouveia, Maxim Gray, Maurizio Roveri, Dzhangar Dzhumashev, Florian Weber, Gianmarco Meier, Paola Luciani, Jochen K. Rossler, Beat W. Schafer, Franck Perez, Michele Bernasconi

CANCERS (2020)

暂无数据